# A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

> **NCT03866239** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 47 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Obinutuzumab
- **DRUG:** Atezolizumab
- **DRUG:** Cibisatamab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT03866239
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-07
- **Primary completion:** 2024-03-13
- **Final completion:** 2024-03-13
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study because development of cibisatamab has been discontinued.
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03866239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03866239, "A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03866239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*